Proper management of hepatic adenoma associated with oral contraceptives.
Four patients with oral contraceptive associated hepatic adenoma have been studied and the literature reviewed. Clinically, these patients can be divided into ruptured and nonruptured hepatoma groups. In instances of ruptured hepatomas, resection only sufficient to control hemorrhage definitely is recommended. In instances of nonruptured hepatomas, major resection should only be attempted by skilled surgeons, and small multiple lesions should be observed. These management principles will deserve re-evaluation as more experience with these tumors accumulates. Until then, a conservative approach is indicated. This includes the avoidance of oral contraception until the biochemistry of these tumors is better clarified.
D000236:Adenoma / Q000139:chemically induced* / Q000601:surgery; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000601:surgery; D002715:Chlormadinone Acetate / Q000009:adverse effects; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects*; D004116:Dimethisterone / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005040:Ethynodiol Diacetate / Q000009:adverse effects; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000601:surgery; D008656:Mestranol / Q000009:adverse effects; D009644:Norgestrel / Q000009:adverse effects; D011247:Pregnancy
D003276:Contraceptives, Oral; D003280:Contraceptives, Oral, Synthetic; D002715:Chlormadinone Acetate; D009644:Norgestrel; D004997:Ethinyl Estradiol; D005040:Ethynodiol Diacetate; D008656:Mestranol; D004116:Dimethisterone